Hone Health reports that the controversial 2002 WHI study misled menopause care, linking HRT to breast cancer and causing ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

Board-certified rheumatologist Dr. Mahsa Tehrani breaks down the benefits of hormone replacement therapy on treating ...

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, as well as the announcement of a controversial drug-review voucher ...

FDA to review nutrients in baby formula: 3 things for parents to know The agency says this is the first comprehensive review since 1988.

The Commissioner of the Food and Drug Administration is promising a full agency review of the safety of chemical abortion drug mifepristone after a new study raised concerns about its effects.

The FDA granted Breakthrough Therapy Designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in May 2021.